MacuLogix® Raises $38.7 Million in Series D

MacuLogix, Inc., a company equipping eye care professionals with the instrument, tools, and education needed to effectively diagnose and treat patients with age-related macular degeneration, completed a $38.7 million Series D round led by new investor Vivo Capital with participation from existing investors Fisk Ventures, Roche Venture Fund, Berwind Private Equity, and Life Sciences Greenhouse of Central Pennsylvania. With this round of funding, Jack B. Nielsen, managing director of Vivo Capital, Nathan Dau, principal of Vivo Capital, and Carole Nuechterlein, head of Roche Venture Fund will join the MacuLogix board of directors.

The company plans to use the funding to further expand the MacuLogix team and company infrastructure to support the sales and practice integration efforts of the AdaptDx automated dark adaptometer, both domestically and internationally. To date, MacuLogix has raised a total of $51 million in venture funding plus $10 million in venture debt.